# Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine

> **NCT05231369** · PHASE1 · UNKNOWN · sponsor: **Chulalongkorn University** · enrollment: 24 (estimated)

## Conditions studied

- Safety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine
- Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine
- Immune Response of 25 ug of ChulaCov19-BNA159 mRNA Vaccine
- Safety of 50 ug of ChulaCov19-BNA159 mRNA Vaccine
- Tolerability of 50 ug of ChulaCov19-BNA159 mRNA Vaccine
- Immune Response of 50 ug of ChulaCov19-BNA159 mRNA Vaccine
- Assess Which Dose is Appropriate to Use

## Interventions

- **BIOLOGICAL:** ChulaCov19 BNA159 mRNA vaccine

## Key facts

- **NCT ID:** NCT05231369
- **Lead sponsor:** Chulalongkorn University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-14
- **Primary completion:** 2023-07-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-02-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05231369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05231369, "Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05231369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*